Follow the Money: In Vivo CAR-T Candidate Development, Modular T Cell Engagers, Wearable Tech, More

Capstan Therapeutics is advancing CPTX2309, their lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders; Clasp is developing modular T cell engagers tailored to each patient’s immune system that are directed to common oncogenic driver mutations, resulting in off-the-shelf, antibody-like medicines that can specifically target a wide variety of hard-to-treat tumor types; Ultrahuman plan to further manufacture capacity and deepen research in the health tracking space; and more.

$182M: Series C for Cystic Fibrosis Treatment

Sionna Therapeutics closed an oversubscribed $182 million Series C financing to support the clinical development of first-in-class small molecules designed to fully restore the function of the cystic fibrosis transmembrane...

Today's Sponsors

Today's Sponsor